Article Sidebar

pdf
Date Published: 21/04/2025
Abstract Views: 86
Views pdf: 41
DOI: https://doi.org/10.51298/vmj.v549i1.13541
Issue
Vol. 549 No. 1 (2025)
Section
Các bài báo
How to Cite
Trần Thị, H., & Phạm Thị, H. . (2025). THE EFFECTIVENESS OF ERYTHROMYCINE IN THE TREATMENT OF PITYRIASIS ROSEA OF GIBERT. Vietnam Medical Journal, 549(1). https://doi.org/10.51298/vmj.v549i1.13541

THE EFFECTIVENESS OF ERYTHROMYCINE IN THE TREATMENT OF PITYRIASIS ROSEA OF GIBERT

Huyền Trần Thị, Hằng Phạm Thị

Main Article Content

Abstract

This interventional study was conducted to evaluate the effectiveness of oral erythromycin in treating pityriasis rosea of Gibert on patients with moderate to severe. The study group received oral erythromycin at 250mg four times daily, divided into two doses and other medications for two weeks; the control group did not receive oral erythromycin. After 4 weeks of treatment, the mean Pruritus Numeric Rating Sacle (PNRS) of the erythromycin group was 1.7±1.3, while that of the control group was 1.6±1.4 (p=0.85). The mean Pityriasis Rosea Severity Score (PRSS) of the erythromycin group was 13.7±6.4, whereas that of the control group was 10.1±6.4 (p=0.03). The cure rate in the erythromycin group was 33.3%, higher than that in the control group (20%) but p>0.05. In the erythromycin group, there were 2 cases of adverse effects, with one case (3.3%) manifested in gastrointestinal symptoms (nausea, epigastric pain) and another case (3.3%) presenting with temporary skin rash. Erythromycin may be suitable for treating moderate to severe pityriasis rosea.

Article Details

Keywords

erythromycine, human herpes virus-6, human herpes virus-7, pityriasis rosea of Gibert

References

1. Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol. 2002; 119(4): 793-797. doi:10.1046/j.1523-1747.2002. 00200.x
2. Broccolo F, Drago F, Careddu AM, et al. Additional Evidence that Pityriasis Rosea Is Associated with Reactivation of Human Herpesvirus-6 and -7. J Invest Dermatol. 2005;124(6): 1234-1240. doi:10.1111/j.0022-202X.2005.23719.x
3. Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2000;42(2):241-244. doi:10.1016/S0190-9622(00)90132-4
4. Aoki Y, Kao PN. Erythromycin Inhibits Transcriptional Activation of NF-κB, but not NFAT, through Calcineurin-Independent Signaling in T Cells. Antimicrob Agents Chemother. 1999; 43(11):2678-2684. doi:10.1128/AAC.43.11.2678
5. Chuh A. Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol. 2003; 17(1): 101-103. doi: 10.1046/j.1468-3083.2003. 00519_4.x
6. Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol. 1995;33(6): 996-999. doi:10.1016/0190-9622(95) 90293-7
7. Ali S. Salloom, Mohammed J.E. Ahmed, Nameer K. Al-Sudany. Treatment of pityriasis rosea with erythromycin and prednisolone: A comparative study. Journal of Natural Science, Biology and Medicine. 2022; 13(2):102-109.
8. Ehsani A, Esmaily N, Noormohammadpour P, et al. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea. Indian J Dermatol. 2010;55(3):246. doi:10.4103/0019-5154.70672